2023 World Conference on Lung Cancer (Posters)-EP07.01. Nomogram for Predictingprognosis andAdjuvant Chemotherapy BenefitsinEarly-stageInvasive Mucinous Lung Adenocarcinoma

EP07.01. Nomogram for Predictingprognosis andAdjuvant Chemotherapy BenefitsinEarly-stageInvasive Mucinous Lung Adenocarcinoma - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to develop a nomogram for predicting prognosis and identifying patients who would benefit from adjuvant chemotherapy (ACT) in early-stage invasive mucinous lung adenocarcinoma (IMA). The study included patients with stage I-IIA IMA who were randomly classified into training and validation cohorts. Independent factors for recurrence-free survival (RFS) were integrated to develop the nomogram. The nomogram was evaluated using the concordance index (C-index), area under the time-dependent receiver operating characteristic curve (AUC), and decision curve analysis (DCA). The predictive value of the nomogram for screening ACT benefits was also assessed. Independent risk factors for RFS included visceral pleural invasion, lymph-vascular invasion, tumor size, smoking history, and lobulation. The nomogram showed better performance than the 8th TNM stage in predicting recurrence, with higher AUC and C-index for 5-year RFS in the validation cohort. DCA analysis demonstrated additional benefits for predicting RFS using the nomogram. In the high-risk group classified by the nomogram, patients who received ACT exhibited superior 5-year RFS compared to non-ACT patients, while no difference in survival was observed in the low-risk group. The nomogram could identify potential candidates who would benefit from ACT in patients with stage I-IIA IMA.

Asset Subtitle

Hua He

Meta Tag

Speaker Hua He

Topic Early-Stage NSCLC: Best Practice

Keywords

nomogram

prognosis

adjuvant chemotherapy

invasive mucinous lung adenocarcinoma

recurrence-free survival

TNM stage

decision curve analysis

high-risk group

low-risk group

potential candidates